Sign up to save your podcasts
Or
Share Targeting the Ribosome: taking on platinum resistance in solid ovarian tumors in a safer way!
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Targeting the Ribosome: taking on platinum resistance in solid ovarian tumors in a safer way!
Today we’ve got Dr. Jonathan Arambula and Dr. Krystle Karoscik of InnovoTex, an oncology therapeutics company developing a platform of smart molecules capable of circumventing drug resistance often seen in treating ovarian cancer. They’re doing it in a safer way – hear about all this and more by listening to the show!
Disclaimer
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an
investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information
conveyed in this material is accurate and is under no obligation to update this information as changes occur.
View all episodes
By Tim Dougherty
4.3
33 ratings
Today we’ve got Dr. Jonathan Arambula and Dr. Krystle Karoscik of InnovoTex, an oncology therapeutics company developing a platform of smart molecules capable of circumventing drug resistance often seen in treating ovarian cancer. They’re doing it in a safer way – hear about all this and more by listening to the show!
Disclaimer
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an
investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information
conveyed in this material is accurate and is under no obligation to update this information as changes occur.
More shows like Life Science and Biotech CEO stories
View all
TED Radio Hour
21,932 Listeners
The Readout Loud
316 Listeners
Biotech 2050 Podcast
61 Listeners
Biotech Hangout
18 Listeners
The Biotech Startups Podcast
22 Listeners